Sign in

You're signed outSign in or to get full access.

Vincent LoPriore

Executive Chairman at Tharimmune
Executive
Board

About Vincent LoPriore

Executive Chairman of Tharimmune since May 9, 2025 and director since April 2025, age 57, with 30+ years in investment banking (Oppenheimer, Legg Mason, C.E. Unterberg Towbin), currently Partner at President Street Global (FINRA broker-dealer) and investment manager of Gravitas Capital LP . He holds significant equity influence via Gravitas (18.45% ownership as of Aug 26, 2025), aligning incentives but centralizing control at the board chair level . The company’s proxy and equity plan disclosures emphasize equity-based incentives, anti-hedging/pledging and clawback, but do not present TSR or financial performance metrics tied to his compensation; company-level performance metrics were not disclosed for his tenure in the documents reviewed .

Past Roles

OrganizationRoleYearsStrategic Impact
Oppenheimer & Co.Investment banking rolesBegan 1989Foundation of capital markets career
Legg Mason, Inc.Senior positionsNot disclosedExpanded sell-side and capital markets experience
C.E. Unterberg, TowbinPartner, led special equitiesNot disclosedCompleted >$150M private placements
Boutique/mid-sized firmsLeadership rolesNot disclosedFocused on capital raising and regulatory navigation

External Roles

OrganizationRoleYearsNotes
President Street Global, LLCPartner & licensed representativeCurrentFINRA-registered broker-dealer
Gravitas Capital LPInvestment managerCurrentManages vehicle that holds THAR shares/warrants
Race to Erase MS; Cure Addiction NowPhilanthropic supporterNot disclosedSector relationships; community initiatives

Fixed Compensation

MetricJun 11, 2025 (post-appointment)Sep 8, 2025 (updated)
Base Salary ($)$285,000 $385,000 (increase of $100,000)
Target Bonus (% of base)60% 60% (unchanged in filing)

Performance Compensation

Incentive TypeMetricWeightingTargetActualPayout MechanicsVesting / Conditions
Annual Cash BonusCompany and individual targetsNot disclosed60% of base Not disclosedCommittee discretion per employment agreement Annual; specifics not disclosed
Equity Awards (options/RSUs)Not disclosedNot disclosedNot disclosedNot disclosedEligible for equity awards per employment agreement Unvested time-based equity accelerates on termination without cause/good reason; vested options exercisable up to 60 months
Change-in-Control SeveranceCompensation protectionNot applicable3x base + target bonus within 12 months of CoC Not applicableIncreased from 2x to 3x by Comp Committee Applies upon termination within 12 months of change of control
ClawbackFinancial restatement recoupmentNot applicableNot applicableNot applicableAdministrator may recoup 3 years of excess incentive compApplies to executive officers per 2023 Plan

Equity Ownership & Alignment

ItemAmount / Detail
Total Beneficial Ownership1,121,770 shares (18.45% of outstanding) as of Aug 26, 2025
Composition944,420 common shares via Gravitas Capital LP; 127,350 warrants via Gravitas; 50,000 options held directly (exercisable)
Unvested / Not ExercisableExcludes 50,000 unvested options held directly; excludes 506,756 Gravitas warrants not exercisable until Jan 25, 2026
Pledging/HedgingCompany policy prohibits hedging and pledging absent pre-clearance; as of Dec 31, 2024 none of directors/executives had pledged shares
Ownership GuidelinesNot disclosed in reviewed documents

Employment Terms

TermDetail
Role & Effective DateExecutive Chairman effective May 9, 2025; employment agreement effective June 11, 2025
Contract Length5 years, auto-renews for successive one-year terms unless 60-day notice
Base Salary & Bonus$285,000 initially; increased to $385,000 on Sep 2, 2025; bonus target 60% of base
Severance (without cause / good reason)12 months base salary and health benefits; immediate vesting of unvested time-based equity; vested options exercisable up to 60 months or option expiry
Change-of-Control EconomicsPayment increased to 3x base salary + target bonus upon termination within 12 months of CoC (from 2x previously)
ClawbackExecutive officers subject to incentive compensation clawback under 2023 Plan
Non-compete / Non-solicitNot disclosed in his agreement excerpt within the 8-K

Board Governance

  • Board Service History: Director since April 2025; Executive Chairman since May 9, 2025. Signed special proxy materials as Executive Chairman/Chairman in September 2025, evidencing board leadership role .
  • Independence: Company identified independent directors as Anderson, Parikh, Kahler, and Stetz; LoPriore (as Executive Chairman) is not listed as independent, indicating non-independence by role .
  • Committees: Committee compositions disclosed for 2024 (Audit: Anderson chair; Compensation: Bui chair; Nominating: Mazur chair); no subsequent committee assignments for LoPriore were disclosed in the reviewed 2025 filings .
  • Board Attendance: 2024 attendance metrics disclosed (none <75%), but LoPriore joined in 2025; no attendance data for him in reviewed documents .

Compensation Structure Analysis

  • Shift toward guaranteed pay: Base salary increased by $100,000 to $385,000 within three months of appointment; change-in-control protection escalated from 2x to 3x base+bonus, raising fixed protection levels relative to at-risk pay .
  • Equity-heavy alignment via external fund: Significant ownership and warrants through Gravitas aligns incentives but concentrates voting power; large blocks of warrants become exercisable Jan 25, 2026, a potential supply overhang near that date .
  • Governance protections: Anti-hedging/pledging policy and clawback regime mitigate misalignment and restatement risk .
  • Equity plan capacity and dilution: 2025 special meeting sought to raise plan shares to 2,000,000 (approx. 17.5% fully diluted) with evergreen features, increasing capacity for future equity grants and potential dilution .

Risk Indicators & Red Flags

  • Enhanced CIC severance (3x base+bonus) increases pay protection and potential misalignment in change-of-control scenarios .
  • Concentrated control: Executive Chairman plus ~18.45% beneficial ownership via related investment vehicle may reduce board independence and elevate conflict potential, though no related-party transactions were reported in 2023–2024 per proxy .
  • Upcoming warrant exercisability (Jan 25, 2026) could introduce selling pressure and dilution risk .

Investment Implications

  • Alignment and influence: High personal/economic stake via Gravitas aligns LoPriore with equity holders but centralizes governance authority at a non-independent Executive Chairman, raising oversight and independence considerations .
  • Pay protection and retention: The 3x CIC multiple and accelerated vesting provisions reduce retention risk but elevate potential payout in strategic transactions; salary uplift signals organizational reliance on executive leadership .
  • Near-term supply risk: Large tranches of warrants not exercisable until Jan 25, 2026 present timing-sensitive overhang; monitor insider activity and secondary offerings around that window .
  • Equity program expansion: The enlarged 2023 Plan capacity (and evergreen feature) supports talent attraction/retention but adds dilution pathways; track grant cadence and overhang metrics over the next 12 months .